Glonghui, April 15 | US hedge fund Shah Capital has recommended that Covid-19 vaccine maker Novavax appoint two new independent directors, Suresh Katta and Venkat Peri, to its board. Shah Capital, which owns about 6.7% of Novavax’s outstanding common stock, said the low share price reflected the board and management’s failure to capitalize on many important competitive advantages and seize opportunities in the overall market. “We welcome the views of our shareholders and value their input on our strategy,” Novavax said in a statement. Novavax is one of the most shorted stocks on the Nasdaq (16175.0941, 0.00, 0.00%) and is currently trading near all-time lows. As of last trading day’s close, the stock had fallen more than 53% in the past 12 months. The stock rose about 3.5% premarket.
Novavax gains about 3.5% pre-market after hedge fund investors recommend two new director candidates
Like (0)
Multi-maturity U.S. Treasury yields rise rapidly
Previous
April 15, 2024 6:06 am
U.S. Treasury yields hit new high this year
Next
April 15, 2024 6:21 am